- #678 Satish Waman Wagh ₹4,700 Cr

About Supriya Lifescience Limited
Data last updated:
Supriya Lifescience Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 26 March 2008 and has been in existence for over 18 years.
Its director Satish Waman Wagh is #678 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L51900MH2008PLC180452. Its GSTIN is 27AALCS8686A1ZX (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 543434 and NSE: SUPRIYA.
The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹16.1 Cr. It is led by directors including Saloni Satish Wagh (Managing Director) and Shivani Satish Wagh (Managing Director).
Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹827.87 Cr, a growth of 18.9% compared to the previous year. For the same year it recorded a net profit of ₹209.14 Cr (net margin 25.3%) and EBITDA of ₹294.46 Cr (EBITDA margin 35.6%). The net worth stands at ₹1,197.74 Cr (up 20.2% YoY). Total assets are valued at ₹1,205.07 Cr (up 20.1% YoY).
The company has about 627 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Supriya Lifescience. As per MCA filings, the company has open charges of ₹188.41 Cr and satisfied charges of ₹283.96 Cr on record. Court records list 28 cases involving the company, including 21 filed by the company and 7 filed against it; 11 cases are pending. The company has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 224 overdue payments to 39 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website supriyalifescience.com.
Company details
CIN history
Supriya Lifescience has one previous CIN (Corporate Identification Number): U51900MH2008PLC180452. The current CIN is L51900MH2008PLC180452, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51900MH2008PLC180452 | Current |
| U51900MH2008PLC180452 | Previous |
Recognitions & Rankings of Supriya Lifescience
Contact details
Supriya Lifescience Limited's registered office is in Mumbai, Maharashtra. Its website is supriyalifescience.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063
- IndustryPharma, API Manufacturers
To see the full contact details of Supriya Lifescience Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Supriya Lifescience operates one associated brand: Supriya Lifescience. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured. | supriyalifescience.com |
Business activity
The main business activity of Supriya Lifescience is manufacturing. In detail, this covers manufacture of chemicals and chemical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 20 | Manufacture of chemicals and chemical products |
To see the full business activity and turnover split of Supriya Lifescience Limited, buy the company report.
Financials of Supriya Lifescience Limited
FY 2025-26 filings availableSupriya Lifescience Limited reported revenue of ₹827.87 Cr (up 18.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 828 | 696 | 570 | 461 | 530 | 391 | 312 |
| Revenue growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| EBITDA | 294 | 261 | 176 | 129 | 214 | 173 | 98.38 |
| EBITDA margin | +35.6% | +37.5% | +30.9% | +28.0% | +40.4% | +44.3% | +31.6% |
| Profit before tax | 275 | 248 | 166 | 123 | 207 | 167 | 96.19 |
| Net profit | 209 | 188 | 119 | 89.94 | 152 | 124 | 73.35 |
| Net profit margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| EPS (₹) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Balance sheet | |||||||
| Total assets | 1,205 | 1,003 | 822 | 728 | 646 | 362 | 253 |
| Net worth | 1,198 | 997 | 815 | 699 | 616 | 269 | 149 |
| Total debt | 5.44 | 5.38 | 5.49 | 22.47 | 27.42 | 72.19 | 82.21 |
| Cash & bank | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Net working capital | 412 | 355 | 321 | 386 | 420 | 190 | 120 |
| Cash flow | |||||||
| Cash from operations | 186 | 165 | 113 | 63.61 | 48.80 | 75.89 | 117 |
| Cash from investing | (176) | (152) | (174) | (124) | (59.82) | (46.80) | (25.14) |
| Cash from financing | (9.88) | (8.23) | (22.36) | (10.28) | 150 | (14.52) | (29.23) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 206 | 190 | 277 | 206 | 200 | 145 | 184 | 186 |
| Revenue growth (YoY) | +3.2% | +30.8% | +50.2% | +11.2% | +20.3% | -9.7% | - | - |
| Other income | 2.29 | 2.65 | 3.48 | 2.61 | 2.73 | 2.67 | 2.98 | 2.10 |
| Total expenses | 161 | 142 | 179 | 135 | 127 | 93.37 | 117 | 120 |
| EBITDA | 45.40 | 47.46 | 97.62 | 71.62 | 72.64 | 51.70 | 67.58 | 65.95 |
| EBITDA margin | +22.0% | +25.0% | +35.3% | +34.7% | +36.4% | +35.6% | +36.7% | +35.5% |
| Depreciation | 9.46 | 8.94 | 8.50 | 6.82 | 6.64 | 6.45 | 6.08 | 4.96 |
| Interest | 0.46 | 0.37 | 0.47 | 0.49 | 0.42 | 0.51 | 0.42 | 0.51 |
| Profit before tax | 37.77 | 40.80 | 92.13 | 66.92 | 68.31 | 47.41 | 64.06 | 62.58 |
| Tax | 8.53 | 16.75 | 17.90 | 17.24 | 17.89 | 12.63 | 13.68 | 15.80 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 206 | 190 | 277 | 206 | 200 | 145 | 184 | 186 |
| Revenue growth (YoY) | +3.2% | +30.8% | +50.2% | +11.2% | +20.3% | -9.7% | - | - |
| Other income | 2.29 | 2.65 | 3.48 | 2.61 | 2.73 | 2.67 | 2.98 | 2.10 |
| Total expenses | 161 | 142 | 179 | 135 | 127 | 93.37 | 117 | 120 |
| EBITDA | 45.40 | 47.46 | 97.62 | 71.62 | 72.64 | 51.70 | 67.58 | 65.95 |
| EBITDA margin | +22.0% | +25.0% | +35.3% | +34.7% | +36.4% | +35.6% | +36.7% | +35.5% |
| Depreciation | 9.46 | 8.94 | 8.50 | 6.82 | 6.64 | 6.45 | 6.08 | 4.96 |
| Interest | 0.46 | 0.37 | 0.47 | 0.49 | 0.42 | 0.51 | 0.42 | 0.51 |
| Profit before tax | 37.77 | 40.80 | 92.13 | 66.92 | 68.31 | 47.41 | 64.06 | 62.58 |
| Tax | 8.53 | 16.75 | 17.90 | 17.24 | 17.89 | 12.63 | 13.68 | 15.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 828 | 696 | 570 | 461 | 530 | 391 | 312 |
| Revenue growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| Other income | 11.49 | 9.82 | 10.64 | 9.49 | 7.58 | 5.01 | 11.07 |
| Total expenses | 533 | 436 | 394 | 332 | 316 | 218 | 213 |
| Employee cost | 96.68 | 80.52 | 67.64 | 55.58 | 49.08 | 32.76 | 18.88 |
| EBITDA | 294 | 261 | 176 | 129 | 214 | 173 | 98.38 |
| EBITDA margin | +35.6% | +37.5% | +30.9% | +28.0% | +40.4% | +44.3% | +31.6% |
| Depreciation | 28.41 | 20.44 | 15.81 | 11.82 | 10.12 | 6.76 | 6.41 |
| Interest | 2.77 | 1.81 | 5.15 | 3.08 | 4.20 | 4.08 | 6.85 |
| Profit before tax | 275 | 248 | 166 | 123 | 207 | 167 | 96.19 |
| Tax | 65.66 | 60.53 | 46.58 | 33.63 | 55.44 | 43.71 | 22.84 |
| Net profit | 209 | 188 | 119 | 89.94 | 152 | 124 | 73.35 |
| Net profit margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| EPS (₹) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.10 | 16.10 | 16.10 | 16.10 | 16.10 | 14.64 | 14.64 |
| Reserves & surplus | 1,182 | 981 | 799 | 683 | 600 | 254 | 134 |
| Shareholders' funds (net worth) | 1,198 | 997 | 815 | 699 | 616 | 269 | 149 |
| Secured loans | 0.00 | 0.00 | 0.00 | 16.63 | 21.30 | 66.38 | 78.12 |
| Unsecured loans | 5.44 | 5.38 | 5.49 | 5.84 | 6.12 | 5.81 | 4.09 |
| Total debt | 5.44 | 5.38 | 5.49 | 22.47 | 27.42 | 72.19 | 82.21 |
| Total liabilities | - | - | 822 | 728 | 646 | 362 | 253 |
| Assets | |||||||
| Gross block | 799 | 534 | 371 | 306 | 223 | 123 | 115 |
| Net block | 689 | 453 | 310 | 262 | 190 | 100 | 98.58 |
| Capital work in progress | 35.55 | 148 | 149 | 67.63 | 43.41 | 78.79 | 40.21 |
| Investments | 98.52 | 63.24 | 63.80 | 25.30 | 0.05 | 0.05 | 0.05 |
| Inventories | 160 | 118 | 85.25 | 116 | 92.31 | 72.48 | 49.46 |
| Sundry debtors | 219 | 134 | 112 | 84.66 | 115 | 73.50 | 51.63 |
| Cash & bank balances | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Loans & advances | 74.39 | 110 | 126 | 107 | 62.14 | 30.21 | 19.81 |
| Total current assets | 532 | 442 | 398 | 465 | 498 | 265 | 196 |
| Total current liabilities | 121 | 86.87 | 76.64 | 78.80 | 77.58 | 75.90 | 75.57 |
| Net working capital | 412 | 355 | 321 | 386 | 420 | 190 | 120 |
| Total assets | 1,205 | 1,003 | 822 | 728 | 646 | 362 | 253 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 | 12.40 |
| Net cash from operating activities | 186 | 165 | 113 | 63.61 | 48.80 | 75.89 | 117 |
| Net cash from investing activities | (176) | (152) | (174) | (124) | (59.82) | (46.80) | (25.14) |
| Net cash from financing activities | (9.88) | (8.23) | (22.36) | (10.28) | 150 | (14.52) | (29.23) |
| Net change in cash | (0.29) | 4.20 | (82.63) | (70.33) | 139 | 14.57 | 62.31 |
| Closing cash | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| EBITDA growth | +12.9% | +48.2% | +36.6% | -39.8% | +23.6% | +76.0% | - |
| PBT growth | +10.6% | +50.0% | +34.2% | -40.4% | +23.9% | +73.9% | -22.0% |
| Net income growth | +11.3% | +57.8% | +32.4% | -40.8% | +22.8% | +68.5% | - |
| Revenue CAGR (3Y) | +21.6% | +9.5% | +13.4% | +13.9% | +24.0% | +22.5% | +19.3% |
| EBITDA CAGR (3Y) | +31.7% | +6.8% | +0.6% | +9.4% | +17.8% | +99.1% | +78.2% |
| Profitability & leverage | |||||||
| Net income margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| Return on capital employed | +25.1% | +27.4% | +22.1% | +18.4% | +42.0% | +55.8% | +46.5% |
| Return on net worth | +19.1% | +20.7% | +15.7% | +13.7% | +34.3% | +59.2% | +60.4% |
| Debt / equity | 0.00 | 0.01 | 0.02 | 0.04 | 0.11 | 0.37 | 0.71 |
| Long-term debt / equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 |
| Interest cover | 1.04 | 0.75 | 3.21 | 2.63 | 2.06 | 2.45 | 7.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.37 | 1.73 | 1.91 | 1.95 | 3.40 | 3.62 | 2.98 |
| Inventory turnover | 6.58 | 7.68 | 6.44 | 4.96 | 7.14 | 7.07 | 7.77 |
| Debtors turnover | 5.17 | 6.36 | 6.59 | 5.17 | 6.24 | 6.89 | 5.59 |
| EPS (₹) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Dividend per share (₹) | 1.00 | 1.00 | 0.80 | 0.60 | 0.60 | 0.54 | 10.00 |
| Book value per share (₹) | 148.81 | 123.84 | 101.31 | 86.91 | 76.50 | 36.70 | 101.84 |
To see the full year-wise statements and ratios of Supriya Lifescience Limited, buy the company report.
Board of directors of Supriya Lifescience Limited
Supriya Lifescience has 10 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Smita Satish Wagh Also directs: Supriya Medi-Chem Private Limited | Whole-Time Director | 26 Mar 2008 | 18 Years 7 Months | Current |
| Neelam Yashpal Arora | Director | 25 Mar 2021 | 5 Years 7 Months | Current |
| Balasaheb Gulabrao Sawant | Whole-Time Director | 26 May 2023 | 3 Years 5 Months | Current |
| Satish Waman Wagh Also directs: Supriya Medi-Chem Private Limited, Sachin Industries Limited, Global Gsa Services India Private Limited and 3 more | Whole-Time Director | 26 Mar 2008 | 18 Years 7 Months | Current |
| Saloni Satish Wagh | Managing Director | 01 Jul 2022 | 4 Years 4 Months | Current |
| Shivani Satish Wagh | Managing Director | 01 Jul 2022 | 4 Years 4 Months | Current |
Auditor
Supriya Lifescience Limited is audited by Kakaria and Associates LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Kakaria and Associates LLP | FY 2025 | 104558W/ W100601 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 68.30%, foreign institutional investors hold 6.20%, domestic institutional investors hold 5.30% and retail and other public shareholders hold 20.20%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% |
| Public | 31.70% | 31.70% | 31.70% | 31.70% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Jun 2026 | 101381192 | Others | ₹40 Cr | Open | |
| 03 May 2024 | 100916191 | Axis Bank Limited | ₹44 Cr | Open | |
| 17 Apr 2024 | 100904329 | Others | ₹30 Cr | Open | |
| 05 Jul 2012 | 10368165 | The Saraswat Cooperative Bank Ltd | ₹2 Cr | Open | |
| 27 Jun 2009 | 10166123 | The Saraswat Cooperative Bank Ltd | ₹10.91 Cr | Open |
To see the full charge records of Supriya Lifescience Limited, buy the company report.
Total charge records: 46 View all charges
Deals & funding
Supriya Lifescience Limited has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024.
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2024 | Market trade | ₹45.93 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Aug 2024 | Market trade | ₹32.16 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Feb 2024 | Market trade | ₹21.49 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Dec 2023 | Market trade | ₹14.27 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| May 2023 | Market trade | ₹10.02 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
To see the full deal history of Supriya Lifescience Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Supriya Lifescience Limited has 28 court cases on record: 21 filed by Supriya Lifescience, 7 filed against it. 11 cases are pending and 17 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 17 | 6 | 10 |
| High courts | 8 | 0 | 0 |
| Supreme Court | 3 | 1 | 1 |
Cases on record (5 of 28)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (2401-Indirect Taxation : Customs Act, Customs Tariff Act, Export, Import and Anti-Dumping duty) | Filed by the company against Union of India and 4 others | Pending |
| Supreme Court | Court case (2406-Indirect Taxation : Goods and Services Tax, Integrated Goods and Services Tax, State Goods and Services Tax, UT Goods and Services Tax.) | Filed against the company by Union of India and 97 others | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Case) | Filed by the company against CSD Lifesciences Private Limited | Pending |
| District court, Ratnagiri, Maharashtra | Civil suit | Filed against the company by Jytra Technology Solutions Pvt Ltd Represented by Rraj Singh Etc 3 and 1 other | Disposed |
| Bombay High Court | Court case (NMA) | Filed by the company against Punjab Chemicals and Crop Protection Ltd | Disposed |
To see the full case history of Supriya Lifescience Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Supriya Lifescience Limited was last rated by Icra on 26 Jul 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 26 Jul 2021 |
To see the full credit ratings and regulatory alerts of Supriya Lifescience Limited, buy the company report.
MSME payment delays
Supriya Lifescience Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 224 overdue payments to 39 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 39)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Spectralab Instruments Private Limited | |||
| Resicast | |||
| Amjey Chem Trade Private Limited | |||
| Acid Industries | |||
| an individual supplier |
To see the full MSME payment records of Supriya Lifescience Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Supriya Lifescience Limited has a workforce of 627 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 627 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 | |
| FY 2015-16 |
To see the full employee and EPFO history of Supriya Lifescience Limited, buy the company report.
GST
Supriya Lifescience has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AALCS8686A1ZX | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Supriya Lifescience Limited, buy the company report.
Recent activity
Supriya Lifescience Limited has 29 board changes on record since 2008: 21 appointments and 8 cessations. The latest: Kothandaraman Hari was appointed as Additional Director on 09 Feb 2026.
109 earlier events are in the company report.
News
Frequently asked questions
Supriya Lifescience is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 26 March 2008 (18+ years old) and is registered under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA.
Supriya Lifescience reported revenue of ₹827.87 Cr for FY 2025-26 (up 18.9% YoY) based on standalone financials.
Supriya Lifescience has 10 current directors:
- Saloni Satish Wagh - Managing Director
- Shivani Satish Wagh - Managing Director
- Smita Satish Wagh - Whole-Time Director
- Balasaheb Gulabrao Sawant - Whole-Time Director
- Satish Waman Wagh - Whole-Time Director
- Neelam Yashpal Arora - Director
- Manish Ishwarlal Panchal - Additional Director
- Kothandaraman Hari - Additional Director
- Ganapati Dadasaheb Yadav - Additional Director
- Sunil Subhash Bhagwat - Additional Director
The latest financial statements of Supriya Lifescience on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Supriya Lifescience is 27AALCS8686A1ZX, registered in Maharashtra.
The CIN (Corporate Identification Number) of Supriya Lifescience is L51900MH2008PLC180452. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Supriya Lifescience is a listed company as per MCA records. Its shares are listed on both BSE (code: 543434) and NSE (symbol: SUPRIYA).
Supriya Lifescience has 28 court cases on record: 21 filed by the company and 7 filed against it. 11 are pending. Most are in the district courts.
Supriya Lifescience was incorporated on 26 March 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.
Supriya Lifescience has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024.
Kothandaraman Hari was appointed as Additional Director on 09 Feb 2026. Manish Ishwarlal Panchal was appointed as Additional Director on 09 Feb 2026. Bhairav Manojbhai Chokshi ceased to be Director on 01 Feb 2025. Supriya Lifescience has 29 board changes on record in total.

